Citadel Advisors’s Columbia Research Enhanced Value ETF REVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-11,016
Closed -$312K 14028
2025
Q4
$312K Buy
11,016
+41
+0.4% +$1.16K ﹤0.01% 10057
2025
Q3
$307K Sell
10,975
-8,816
-45% -$240K ﹤0.01% 10319
2025
Q2
$520K Buy
+19,791
New +$491K ﹤0.01% 8537
2025
Q1
Sell
-13,556
Closed -$335K 15398
2024
Q4
$335K Buy
+13,556
New +$350K ﹤0.01% 9428
2024
Q3
Sell
-17,206
Closed -$401K 15072
2024
Q2
$401K Buy
+17,206
New +$400K ﹤0.01% 8513
2023
Q4
Sell
-13,432
Closed -$274K 15088
2023
Q3
$274K Buy
+13,432
New +$283K ﹤0.01% 9331
2022
Q4
Sell
-14,500
Closed -$260K 15357
2022
Q3
$260K Buy
+14,500
New +$284K ﹤0.01% 9882

Other funds holding REVS

Citadel Advisors's REVS Position: Q1 2026 in Review

Citadel Advisors sold out of Columbia Research Enhanced Value ETF (REVS) in Q1 2026, closing a stake of 11,016 shares — an estimated $312K sold.

Citadel Advisors first reported a position in REVS in Q3 2022 and held it in 7 quarters. The position peaked at $520K in Q2 2025. 37 funds tracked by Wall St. Rank hold REVS as of Q1 2026.

  • Citadel Advisors reported no remaining Columbia Research Enhanced Value ETF position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 11,016 Columbia Research Enhanced Value ETF shares in Q1 2026, an estimated $312K.
  • Citadel Advisors first reported a position in Columbia Research Enhanced Value ETF in Q3 2022 and held it in 7 quarters.
  • Citadel Advisors's Columbia Research Enhanced Value ETF position peaked at $520K in Q2 2025.
  • 37 funds tracked by Wall St. Rank held Columbia Research Enhanced Value ETF as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.